- ByInvesting.com
- •
Amylin Pharmaceuticals, LLC, a biopharmaceutical company, engages in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. The company offers BYDUREON (exenatide extended-release for injectable suspension), a once-weekly diabetes treatment as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. Its products include BYETTA (exenatide) injection for the treatment of type 2 diabetes; and SYMLIN (pramlintide acetate) injection for the treatment of type 1 and type 2 diabetes. The company develops a dual chamber cartridge pen configuration of BYDUREON that allow patients to mix and administer BYDUREON from a pre-filled pen device. The company markets its products to healthcare providers, managed healthcare organizations, hospitals, wholesalers and pharmacies, government purchasers, and other third-party payers primarily in the United States. It has a collaboration agreement with Alkermes Controlled Therapeutics, Inc. II for the development, manufacture, and commercialization of BYDUREON; and a strategic relationship with Biocon, Limited, to develop pharmaceutical products for diabetes. The company was founded in 1987 and is headquartered in San Diego, California. Amylin Pharmaceuticals, LLC operates as a subsidiary of AstraZeneca PLC.